This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
See you next year! October 2025
Japan

Delivered as a Hybrid Event

Dr. Yoshifumi Maya, Ph.D.
Group Manager at Nihon Medi-Physics
Speaker

Profile

In 2008, Yoshifumi Maya joined Nihon Medi-Physics Co., Ltd., and was engaged in research and development of radiopharmaceuticals. From 2013 to 2015, he belonged to the Department of Nuclear Medicine of University of Wuerzburg, Germany, as a guest scientist. He received a PhD in pharmacy from Chiba University in 2016. Since 2022, he has been working as a group manager at the research center, where he is in charge of non-clinical research on PET diagnostics and Targeted Alpha Therapy products.

Agenda Sessions

  • Development of NMT25/NMK89 As Theranostics Agents with Novel Platform Technology: 225Ac/89Zr-labeled Antibody Targeting MUC5AC for Pancreatic Cancer

    11:45